Journal of Cancer Prevention

eISSN 2288-3657
pISSN 2288-3649
Fig. 3.

Download original image

Fig. 3. Effect of imatinib and GNF-5 on Skp2 overexpression HepG2 cells. (A) Cell viability was measured after treatment with imatinib or GNF-5 for 0, 24, 48, or 72 hours in HepG2 cells expressing mock or Skp2. (B) Cell cycle distribution was detected in HepG2 cells expressing mock or Skp2 by flow cytometry. (C) Effects of Skp2 overexpression on the levels of Skp2, p21, p27, CDK4, cyclin D1, cyclin E1 and tubulin proteins in HepG2 cells treated with 20 μM of imatinib or GNF-5 for 24 hours as measured by Western blot analysis. Skp2, S-phase kinase-associated protein 2; CDK4, cyclin-dependent kinase 4. *P < 0.05; **P < 0.01; ***P < 0.001.
J Cancer Prev 2020;25:252~257 https://doi.org/10.15430/JCP.2020.25.4.252
© J Cancer Prev
Copyright © Korean Society of Cancer Prevention. / Powered by INFOrang Co., Ltd